Aripiprazole as the causative agent of neuroleptic malignant syndrome: A case report [2]

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 9, Issue 2, 2007, Pages 148-150

  Molina, Daniel ^a   Tingle, Leslie E ^b   Lu, Xiaohui ^b  

^a U S PUBLIC HEALTH SERVICE   (United States)

^b BAYLOR HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BENZATROPINE; LORAZEPAM;

AGED; ANAMNESIS; CASE REPORT; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LETTER; LEUKOCYTOSIS; MENTAL HEALTH; NEUROLEPTIC MALIGNANT SYNDROME; PARANOID SCHIZOPHRENIA; SYMPTOMATOLOGY;

EID: 34247272541     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/pcc.v09n0211b     Document Type: Letter

References (19)

1. Velamoor VR. Neuroleptic malignant syndrome: recognition, prevention and management. Drug Saf 1998;19:73
2. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993;77:185
3. Logo A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome: a case review. Hum Psychopharmacol 2003;18:301
4. Kane JM, Carson WH, Saha AR. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-771
5. Expert Consensus Guideline Series: Using Antipsychotic Agents in Older Patients. J Clin Psychiatry 2004;65(suppl 2):5-99
6. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
7. Miyamoto S, Duncan GE, Marx CE, et al. Treatment for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10:79-104
8. Gardner D, Baldessarini R, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005;172:1703-1711
9. Buckly PF. Aripiprazole: efficacy and tolerability profile of a novel-acting atypical antipsychotic. Drugs Today 2003;39:145-151
10. Caroff S, Mann S, Campbell E. Atypical antipsychotics and neuroleptic malignant syndrome. Psych Annals 2000;30:314-321
11. Hynes A, Vickar E. Case study: neuroleptic malignant syndrome without pyrexia. J Am Acad Child Adolesc Psychiatry 1996;35:959-962
12. Adityanjee. The myth of elevated serum creatinine phosphokinase level and neuroleptic malignant syndrome. Br J Psychiatry 1991;158:706-707
13. Roth SD, Addonizio G, Susman VL. Diagnosing and treating neuroleptic malignant syndrome: review of experience with children and adolescents. J Adolesc Psychopharmacol 1992;2:183-198
14. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142:1137-1145
15. Hess JW, MacDonald RP, Frederick RJ, et al. Serum creatine phosphokinase (CPK) activity in disorders of heart and skeletal muscle. Ann Intern Med 1964;61:1015-1028
16. Kokko JP. Rhabdomyolysis. In: Goldman L, Ausiello DA, eds. Cecil Textbook of Medicine. 22nd ed. Philadelphia, Pa: WB Saunders Company; 2004:649
17. Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol 2004;19:351-353
18. Spalding S, Alessi NE, Radwan K. Aripiprazole and atypical neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 2004;43:1457-1458
19. Hanrahan NP, Sullivan-Marx EM. Practice patterns and potential solutions to the shortage of providers of older adult mental health services. Policy Polit Nurs Pract 2005;6:236-245